Pipeline

Our diverse pipeline includes innovative therapeutics and biobetters.
We focus on three key therapeutic areas: orphans, cancers and immune disorders.

HyTropin (long-acting hGH, GX-H9)

Indication Research Pre-Clinical Clinical Phase Site
I II III
Adult Growth Hormone Deficiency
 
 
EU/KR
Pediatric Growth Hormone Deficiency
 
 

HyPoietin (long-acting EPO, GX-E2)

Indication Research Pre-Clinical Clinical Phase Site
I II III
CKD-induced Anemia
 
 
KR

HyGrastim (long-acting G-CSF, GX-G3)

Indication Research Pre-Clinical Clinical Phase Site
I II III
Neutropenia
 
 
EU

HyGlutide (long-acting GLP-1, GX-G6)

Indication Research Pre-Clinical Clinical Phase Site
I II III
Type 2 Diabetes
 
 
EU

Papitrol-188 (HPV DNA Vaccine)

Indication Regimen Research Pre-Clinical Clinical Phase Site
I II III
Pre-Cervical Cancer
(HSIL)
Mono
 
 
EU
Cervical Cancer Pembrolizumab Combo
 
 
KR

Multi-Target Antibody Drug Candidates

Areas Indication Research Pre-Clinical Clinical Phase Site
I II III
Multi-Specific
(Bi-, Tri-)
Cancer
 
 
KR

HyLeukin (IL-7-hyFc)

Areas Indication Regimen Research Pre-Clinical Clinical Phase Site
I II III
Immuno-Oncology Solid Tumor Mono
 
 
KR
Glioblastoma Mono
 
 
KR
Triple Negative Breast Cancer Pembrolizumab combo
 
 
KR

HyLeukin (IL-7-hyFc), Co-developing with NIT

Areas Indication Regimen Research Pre-Clinical Clinical Phase Site
I II III
Immuno-Oncology Glioblastoma Mono
 
 
US
Chemo combo
 
 
US
Skin Cancer
(Melanoma, etc.)
Atezolizumab combo
 
 
US